ScoreWhy is Concord Biotech Ltd ?
1
High Management Efficiency with a high ROE of 17.91%
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 7.33% and Operating profit at 0.42% over the last 5 years
4
Flat results in Mar 26
- PAT(Latest six months) At Rs 155.69 cr has Grown at -28.02%
5
With ROE of 13.1, it has a Very Expensive valuation with a 7 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -34.44%, its profits have fallen by -29.1%
6
Majority shareholders : Promoters
7
Underperformed the market in the last 1 year
- Even though the market (BSE500) generated negative returns of -2.24% in the last 1 year, its fall in the stock was much higher with a return of -34.44%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Concord Biotech should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Concord Biotech for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Concord Biotech
-34.44%
-0.86
40.22%
Sensex
-7.55%
-0.58
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.33%
EBIT Growth (5y)
0.42%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.64
Tax Ratio
24.78%
Dividend Payout Ratio
24.63%
Pledged Shares
0
Institutional Holding
17.02%
ROCE (avg)
27.54%
ROE (avg)
17.91%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
54
Industry P/E
34
Price to Book Value
7.01
EV to EBIT
46.87
EV to EBITDA
37.37
EV to Capital Employed
8.56
EV to Sales
13.02
PEG Ratio
NA
Dividend Yield
0.79%
ROCE (Latest)
18.27%
ROE (Latest)
13.06%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-4What is not working for the Company
PAT(Latest six months)
At Rs 155.69 cr has Grown at -28.02%
Loading Valuation Snapshot...
Here's what is not working for Concord Biotech
Profit After Tax (PAT) - Latest six months
At Rs 155.69 cr has Grown at -28.02%
Year on Year (YoY)MOJO Watch
Near term PAT trend is negative
PAT (Rs Cr)
Non Operating Income - Quarterly
Highest at Rs 15.35 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
